Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 05, 2015 4:32 AM ET

Healthcare Providers and Services

Company Overview of Joslin Diabetes Center, Inc.

Company Overview

Joslin Diabetes Center, Inc. operates a diabetes treatment, research, and education institution. It offers research programs for preventing and curing type 1 and type 2 diabetes and their long-term complications. The company also provides diabetes care services for adult and pediatric patients. In addition, it develops and markets programs, products, and services for the availability of the company’s knowledge and expertise to people with diabetes and the clinicians caring for them. Joslin Diabetes Center, Inc. was founded in 1898 and is headquartered in Boston, Massachusetts.

One Joslin Place

Boston, MA 02215

United States

Founded in 1898





Key Executives for Joslin Diabetes Center, Inc.

Chief Executive Officer, President and Trustee
Age: 64
Chief Financial Officer
Age: 57
Chief Scientific Officer, Senior Vice President and Trustee
Chief Academic Officer
Senior Vice President of Medical Affairs
Compensation as of Fiscal Year 2015.

Joslin Diabetes Center, Inc. Key Developments

Joslin Diabetes Center and Daegu-Gyeongbuk Free Economic Zone Sign MoU to Explore Opportunities to Collaborate

Joslin Diabetes Center and Daegu-Gyeongbuk Free Economic Zone have signed a memorandum of understanding formalizing their mutual strong commitment to navigate avenues for potential partnership. The MoU signing is an important step towards establishing a partnership that will allow Joslin to potentially establish a physical presence in the Daegu-Gyeongbuk area, bringing Joslin’s mission of preventing, treating and curing diabetes to the region. There were an estimated 2.7 million cases of diabetes in the Republic of Korea in 2014.

MedImmune and Joslin Diabetes Center Announce New Research Collaboration Focused on Advancing Metabolic Disease Research

MedImmune and Joslin Diabetes Center announced a three-year research collaboration to develop new medicines for the treatment of diabetes, obesity, and related metabolic disorders. MedImmune and Joslin researchers will work collaboratively on research projects to identify new drug candidates. Three initial projects have been identified, focusing on several key areas including protecting and regenerating the insulin producing beta cells, increasing the caloric utilization of fat depots ('beiging' white fat or expanding brown fat), and replicating the beneficial effects of bariatric surgery pharmacologically. The collaboration is structured with the potential for more projects to be added as new compelling science is identified. Under the terms of the agreement, MedImmune will provide research funding to Joslin and bring drug development expertise and capabilities to complement Joslin's early metabolic disease research competencies and clinical care infrastructure. MedImmune has the option to license development and commercial rights to projects emerging from the collaboration.

EKF Diagnostics Enters into Multi-Year, Collaborative Relationship with Joslin Diabetes Center in Support of the Ongoing Clinical and Commercial Translation

EKF Diagnostics has entered a multi-year, collaborative relationship with Joslin Diabetes Center in support of the ongoing clinical and commercial translation of TNFR1 & 2 biomarkers. These novel biomarkers can help identify patients with Type 1 and Type 2 diabetes that are at an increased risk of developing end stage renal disease (ESRD), up to ten years in advance. The new agreement between Joslin, an affiliate of Harvard Medical School, and EKF is part of Joslin's Corporate Liaison Program (CLP). This program seeks to accelerate development, validation and market introduction of unique products and solutions that advance treatments and care for diabetes and its complications. As globally recognized leaders in the field of diabetes research, Joslin has created the CLP in order to foster industry partnerships within the pharmaceutical, biotechnology, food and device industries. The role of the CLP is to help engage corporate partners, such as EKF, with Joslin's capabilities in advisory services, clinical expertise, and research infrastructure. This enables Joslin to work closely with an industry partner to customize its offerings towards a defined product program or a range of corporate priorities within diabetes management.

Similar Private Companies By Industry

Company Name Region
Trenton Hyperbaric LLC United States
Homestead Long Term Care Management LLC United States
Advance Hi-Tech Nursing, Inc. United States
Shasta Regional Medical Center, Inc. United States
Forest City Building Ltd United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Joslin Diabetes Center, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at